[1] |
Harry O, Yasin S, Brunner H. Childhood-onset systemic lupus erythematosus: a review and update[J]. J Pediatr, 2018, 196:22-30.e2. DOI: 10.1016/j.jpeds.2018.01.045.
|
[2] |
Wu CY, Li CF, Wu QJ, et al. Chinese systemic lupus erythematosus treatment and research group registry Ⅸ:clinical features and survival of childhood-onset systemic lupus erythematosus in China[J]. Chin Med J (Engl), 2017, 130(11): 1276-1282. DOI: 10.4103/0366-6999.206346.
|
[3] |
Hiraki LT, Benseler SM, Tyrrell PN, et al. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study[J]. J Pediatr, 2008, 152(4):550-556. DOI: 10.1016/j.jpeds.2007.09.019.
|
[4] |
|
[5] |
中华医学会风湿病学分会. 系统性红斑狼疮诊治指南(草案)[J]. 中华风湿病学杂志,2003, 7(8):508-513.
|
[6] |
Levy DM, Kamphuis S. Systemic lupus erythematosus in children and adolescents [J]. Pediatr Clin North Am, 2012, 59(2): 345-364. DOI: 10.1016/j.pcl.2012.03.007.
|
[7] |
Yu F, Wu LH, Tan Y, et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system [J]. Kidney Int, 2010, 77(9): 820-v9. DOI: 10.1038/ki.2010.13.
|
[8] |
Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices [J]. Kidney Int, 2018, 93(4): 789-796. DOI: 10.1016/j.kint.2017.11.023.
|
[9] |
|
[10] |
Yin X, Kim K, Suetsugu H, et al. Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus[J]. Ann Rheum Dis, 2021, 80(5): 632-640. DOI: 10.1136/annrheumdis-2020-219209.
|
[11] |
Yu C, Li P, Dang X, et al. Lupus nephritis: new progress in diagnosis and treatment[J]. J Autoimmun, 2022, 132, 102871. DOI: 10.1016/j.jaut.2022.102871.
|
[12] |
Obrişcǎ B, Sorohan B, Tuţǎ L, et al. Advances in lupus nephritis pathogenesis: from bench to bedside [J]. Int J Mol Sci, 2021, 22(7): 3766. DOI: 10.3390/ijms22073766.
|
[13] |
Flores-Mendoza G, Sansón SP, Rodríguez-Castro S, et al. Mechanisms of tissue injury in lupus nephritis[J]. Trends Mol Med, 2018, 24(4): 364-378. DOI: 10.1016/j.molmed.2018.02.003.
|
[14] |
Woo JMP, Parks CG, Jacobsen S, et al. The role of environmental exposures and gene-environment interactions in the etiology of systemic lupus erythematous [J]. J Intern Med, 2022, 291(6): 755-778. DOI: 10.1111/joim.13448.
|
[15] |
Li R, Meng X, Chen B, et al. Gut Microbiota in Lupus: a butterfly effect? [J]. Curr Rheumatol Rep, 2021, 23(4): 27. DOI: 10.1007/s11926-021-00986-z.
|
[16] |
Truedsson L, Bengtsson AA, Sturfelt G. Complement deficiencies and systemic lupus erythematosus [J]. Autoimmunity, 2007, 40(8): 560-566. DOI: 10.1080/08916930701510673.
|
[17] |
Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type Ⅰ IFN production in pediatric systemic lupus erythematosus [J]. Sci Transl Med, 2011, 3(73): 73ra20. DOI: 10.1126/scitranslmed.3001201.
|
[18] |
Liu J, Zhang X, Cao X. Dendritic cells in systemic lupus erythematosus: from pathogenesis to therapeutic applications[J]. J Autoimmun, 2022, 132: 102856. DOI: 10.1016/j.jaut.2022.102856.
|
[19] |
Nie Y, Zhao L, Zhang X. B cell aberrance in lupus: the ringleader and the solution [J]. Clin Rev Allergy Immunol, 2022, 62(2): 301-323. DOI: 10.1007/s12016-020-08820-7.
|
[20] |
Banchereau R, Hong S, Cantarel B, et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients [J]. Cell, 2016, 165(6): 1548-1550. DOI: 10.1016/j.cell.2016.05.057.
|
[21] |
Klavdianou K, Lazarini A, Fanouriakis A. Targeted biologic therapy for systemic lupus erythematosus: emerging pathways and drug pipeline [J]. Bio Drugs, 2020, 34(2): 133-147. DOI: 10.1007/s40259-020-00405-2.
|
[22] |
Shan J, Jin H, Xu Y. T cell metabolism: a new perspective on Th17/Treg Cell imbalance in systemic lupus erythematosus[J]. Front Immunol, 2020, 11: 1027.DOI: 10.3389/fimmu.2020.01027.
|
[23] |
|
[24] |
Arazi A, Rao DA, Berthier CC, et al. The immune cell landscape in kidneys of patients with lupus nephritis[J]. Nat Immunol, 2019, 20(7): 902-914. DOI: 10.1038/s41590-019-0398-x.
|
[25] |
|
[26] |
Der E, Suryawanshi H, Morozov P, et al. Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways[J]. Nat Immunol, 2019, 20(7): 915-927. DOI: 10.1038/s41590-019-0386-1.
|
[27] |
Dhingra S, Qureshi R, Abdellatif A, et al. Tubulointerstitial nephritis in systemic lupus erythematosus: innocent bystander or ominous presage [J]. Histol Histopathol, 2014, 29(5): 553-565. DOI: 10.14670/hh-29.10.553.
|
[28] |
Hsieh C, Chang A, Brandt D, et al. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring [J]. Arthritis Care Res (Hoboken), 2011, 63(6): 865-874. DOI: 10.1002/acr.20441.
|
[29] |
|
[30] |
Kozeny GA, Barr W, Bansal VK, et al. Occurrence of renal tubular dysfunction in lupus nephritis [J]. Arch Intern Med, 1987, 147(5): 891-895.
|
[31] |
Howie AJ, Turhan N, Adu D. Powerful morphometric indicator of prognosis in lupus nephritis[J]. QJM, 2003, 96(6): 411-420. DOI: 10.1093/qjmed/hcg074.
|
[32] |
Pagni F, Galimberti S, Galbiati E, et al. Tubulointerstitial lesions in lupus nephritis: international multicentre study in a large cohort of patients with repeat biopsy[J]. Nephrology (Carlton), 2016, 21(1): 35-45. DOI: 10.1111/nep.12555.
|
[33] |
Gomes MF, Mardones C, Xipell M, et al. The extent of tubulointerstitial inflammation is an independent predictor of renal survival in lupus nephritis [J]. J Nephrol, 2021, 34(6): 1897-1905. DOI: 10.1007/s40620-021-01007-z.
|
[34] |
Song J, Yu J, Prayogo GW, et al. Understanding kidney injury molecule 1: a novel immune factor in kidney pathophysiology [J]. Am J Transl Res, 2019, 11(3): 1219-1229.
|
[35] |
Giannico G, Fogo AB. Lupus nephritis: is the kidney biopsy currently necessary in the management of lupus nephritis? [J]. Clin J Am Soc Nephrol, 2013, 8(1): 138-145. DOI: 10.2215/CJN.03400412.
|
[36] |
Humphreys BD, Xu F, Sabbisetti V, et al. Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis [J]. J Clin Invest, 2013, 123(9): 4023-4035. DOI: 10.1172/jci45361.
|
[37] |
Yi A, Lee CH, Yun YM, et al. Effectiveness of plasma and urine neutrophil gelatinase-associated lipocalin for predicting acute kidney injury in high-risk patients [J]. Ann Lab Med, 2021, 41(1): 60-67. DOI: 10.3343/alm.2021.41.1.60.
|
[38] |
Rubinstein T, Pitashny M, Putterman C. The novel role of neutrophil gelatinase-B associated lipocalin (NGAL)/lipocalin-2 as a biomarker for lupus nephritis [J]. Autoimmun Rev, 2008, 7(3): 229-234. DOI: 10.1016/j.autrev.2007.11.013.
|
[39] |
Satirapoj B, Kitiyakara C, Leelahavanichkul A, et al. Urine neutrophil gelatinase-associated lipocalin to predict renal response after induction therapy in active lupus nephritis [J]. BMC Nephrol, 2017, 18(1): 263. DOI: 10.1186/s12882-017-0678-3.
|
[40] |
Sun F, Teng J, Yu P, et al. Involvement of TWEAK and the NF-κB signaling pathway in lupus nephritis [J]. Exp Ther Med, 2018, 15(3): 2611-2619. DOI: 10.3892/etm.2018.5711.
|
[41] |
Rovin BH, Song H, Birmingham DJ, et al. Urine chemokines as biomarkers of human systemic lupus erythematosus activity[J]. J Am Soc Nephrol, 2005, 16(2): 467-473. DOI: 10.1681/asn.2004080658.
|
[42] |
Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus [J]. Arthritis Rheumatol, 2019, 71(9): 1400-1412. DOI: 10.1002/art.40930.
|
[43] |
Yung S, Tsang RC, Sun Y, et al. Effect of human anti-DNA antibodies on proximal renal tubular epithelial cell cytokine expression: implications on tubulointerstitial inflammation in lupus nephritis [J]. J Am Soc Nephrol, 2005, 16(11): 3281-3294. DOI: 10.1681/asn.2004110917.
|
[44] |
Li SL, Liou LB, Fang JT, et al. Symptomatic renal tubular acidosis (RTA) in patients with systemic lupus erythematosus: an analysis of six cases with new association of type 4 RTA [J]. Rheumatology (Oxford), 2005, 44(9): 1176-1180. DOI: 10.1093/rheumatology/keh705.
|